These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Modification of Parkinsonism--chronic treatment with L-dopa. Cotzias GC; Papavasiliou PS; Gellene R N Engl J Med; 1969 Feb; 280(7):337-45. PubMed ID: 4178641 [No Abstract] [Full Text] [Related]
3. Parkinsonism and DOPA. Cotzias GC; Papavasiliou PS; Gellene R; Aronson RB Trans Assoc Am Physicians; 1968; 81():171-83. PubMed ID: 4889342 [No Abstract] [Full Text] [Related]
4. [Treatment of Parkinsonism with L-dopa--with special reference to clinical effects, side effects and urinary metabolites of catecholamines]. Uono M; Tanabe H; Yano Y; Nakao K No To Shinkei; 1970 Sep; 22(9):1091-101. PubMed ID: 5536082 [No Abstract] [Full Text] [Related]
5. L-Dopa treatment in Parkinson's Disease. Rinne UK; Sonninen V; Siirtola T Eur Neurol; 1970; 4(6):348-69. PubMed ID: 4932969 [No Abstract] [Full Text] [Related]
6. Studies on the metabolism and excretion of L-3,4-dihydroxyphenylalanine (L-DOPA) in human beings by gas chromatography. Imai K; Sugiura M; Kubo H; Tamura Z; Oya K Chem Pharm Bull (Tokyo); 1972 Apr; 20(4):759-64. PubMed ID: 5045616 [No Abstract] [Full Text] [Related]
7. Serial determinations of homovanillinic acid in the cerebrospinal fluid of Parkinson patients treated with L-dopa. Bertler A; Jeppsson PG; Nordgren L; Rosengren E Acta Neurol Scand; 1971; 47(4):393-402. PubMed ID: 4941731 [No Abstract] [Full Text] [Related]
8. Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease. Muenter MD; Sharpless NS; Tyce GM Mayo Clin Proc; 1972 Jun; 47(6):389-95. PubMed ID: 5041685 [No Abstract] [Full Text] [Related]
9. Levodopa in Parkinsonism: potentiation of central effects with a peripheral inhibitor. Papavasiliou PS; Cotzias GC; Düby SE; Steck AJ; Fehling C; Bell MA N Engl J Med; 1972 Jan; 286(1):8-14. PubMed ID: 4550085 [No Abstract] [Full Text] [Related]
10. Biochemical investigations in patients with Parkinson's disease treated with L-dopa. Jequier E; Dufresne JJ Neurology; 1972 Jan; 22(1):15-21. PubMed ID: 5061836 [No Abstract] [Full Text] [Related]
11. Combined L-dopa and amantadine in Parkinsonism. Pollock M; Jorgensen PB Aust N Z J Med; 1972 Aug; 2(3):252-5. PubMed ID: 4564049 [No Abstract] [Full Text] [Related]
12. Pyridoxine, DOPA, and Parkinsonism. Yahr MD; Duvoisin RC; Côté L; Cohen G Adv Biochem Psychopharmacol; 1972; 4():185-94. PubMed ID: 4555927 [No Abstract] [Full Text] [Related]
13. Metabolism and clinical assessment of L-dopa in parkinsonism. Ericsson AD; McCann D; Sharpless N; Reveno W Neurology; 1970 Apr; 20(4):402. PubMed ID: 4935027 [No Abstract] [Full Text] [Related]
14. Treatment of Parkinson's disease with amantadine and L-Dopa. Rinne UK; Sonninen V; Siirtola T Eur Neurol; 1972; 7(4):228-40. PubMed ID: 4556618 [No Abstract] [Full Text] [Related]